UCLA Develops Blood Test That Detects Multiple Cancers in 1,061 People for Under $20
Updated
Updated · ScienceDaily · Aug 11
UCLA Develops Blood Test That Detects Multiple Cancers in 1,061 People for Under $20
1 articles · Updated · ScienceDaily · Aug 11
Summary
MethylScan, a UCLA blood test evaluated in 1,061 people, detected multiple cancers, liver diseases and organ damage signals from a single vial by reading DNA methylation patterns in cell-free DNA.
At 98% specificity, the test identified about 63% of cancers across all stages and roughly 55% of early-stage cases; in high-risk liver cancer patients, it detected nearly 80% at just above 90% specificity.
The approach cuts away unmethylated background DNA—80% to 90% of circulating fragments come from normal blood cells—letting researchers reach 300× sequencing depth with 5 gigabases of data, or less than $20 if sequencing stays below $4 per gigabase.
Methylation patterns also pointed to tissue of origin and distinguished liver disease types with about 85% accuracy, suggesting the test could guide follow-up imaging and reduce some invasive liver biopsies.
Researchers said larger prospective trials are still needed, but the PNAS study moves medicine closer to a single affordable blood test for broad early disease screening.
Could a single, low-cost blood test predicting exact organ damage render traditional biopsies and expensive medical scans obsolete?
How exactly does this new blood test filter out normal DNA noise without accidentally erasing the faintest whispers of early-stage cancer?
If a new epigenetic test finds silent organ damage before symptoms appear, will it save lives or trigger massive medical over-treatment?
MethylScan and the Future of Cancer Screening: How UCLA’s $20 Multi-Cancer Blood Test Could Disrupt a $500 Million Market
Overview
UCLA’s MethylScan technology uses special enzymes to remove background DNA from blood samples, making it possible to focus on disease-related signals with much less sequencing data. This innovation drops the raw sequencing cost to under $20 per test, making large-scale screening affordable and able to bypass complex insurance hurdles. MethylScan’s machine learning can pinpoint which organ is affected, helping doctors target follow-up tests and reducing the need for invasive procedures like liver biopsies. By finding cancer early, MethylScan has the potential to greatly improve survival rates, but widespread adoption still depends on regulatory approval and more clinical evidence.